TICKERNERD
Menu
WVEWVEHealthcare · Biotechnology

WVE Stock Forecast: Wave Life Sciences, Inc. Price Predictions for 2026-2027

Last close, 4 Nov 2026
$3.62
+1.12% on the day

The 21 Wall Street analysts covering Wave Life Sciences, Inc. hold a median 12-month price target of $14 — +286.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 22 of 100 as at 3 Nov 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$706.1M
Ticker Nerd rank
22/ 100
Median analyst target
$14
Analysts covering
21
Revenue$2.3M−73.9% y/y
Operating income−$73.8M
Net income−$69.4M
Free cash flow−$54.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−0.5%
1M
−4.2%
YTD
−78.7%
1Y
−54.8%
From 52W high
−83.0%
From 52W low
+17.2%
$3
$21
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

WVE stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Wave Life Sciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 3 Nov 2026
22/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
79
Quality
52
Size
48
Value
46
Accruals
30
Volatility
22
Growth
20
Issuance
13
Momentum
13

Revisions (79): Analysts have, on balance, been raising their forecasts.

Momentum (13): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

WVE stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on WVE, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40$50Jan 26Apr 26Jul 26Oct 26WVEHigh $44Median $14Low $10

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says21 analysts
19 Buy2 Hold0 Sell
Low $10Median $14High $44

The green dot is the last close — the median target sits +286.7% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 2 moved their price target up and 5 moved it down.

DateFirmActionRatingTarget
29 Oct 2026Canaccord GenuityMaintainsBuy$42 → $44
28 Oct 2026OppenheimerMaintainsOutperform$32 → $29
16 Oct 2026William BlairInitiatesOutperform—
16 Oct 2026William BlairInitiatesOutperform—
15 Oct 2026UBSInitiatesBuy—
15 Oct 2026UBSInitiatesBuy$11
1 Oct 2026Ladenburg ThalmannInitiatesBuy$10
1 Oct 2026Ladenburg ThalmannInitiatesBuy—
23 Sept 2026JP MorganDowngradeNeutral—
23 Sept 2026JP MorganDowngradeNeutral—
4 Aug 2026MizuhoMaintainsOutperform$27 → $23
4 Aug 2026MizuhoMaintainsOutperform—
31 July 2026B. Riley SecuritiesMaintainsBuy—
31 July 2026B. Riley SecuritiesMaintainsBuy$31 → $22
31 July 2026CitigroupMaintainsBuy$24 → $19
31 July 2026CitigroupMaintainsBuy—
31 July 2026WedbushMaintainsOutperform$15 → $12
31 July 2026WedbushMaintainsOutperform—
20 May 2026Wells FargoMaintainsOverweight—
20 May 2026Wells FargoMaintainsOverweight$13 → $14

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

WVE appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

WVE vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 4 Nov 2026, Wave Life Sciences, Inc. returned −54.8% against +12.9% for the S&P 500, dividends included.

WVE vs S&P 500, last 12 monthsTotal return, rebased to 100
50100150200250Jan 26Apr 26Jul 26Oct 26WVES&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

WVE analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Wave Life Sciences, Inc. (WVE) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−3.0×

Cheaper than 88% of US stocks

Price / sales
10.0×

Cheaper than 13% of US stocks

Price / book
1.8×

Cheaper than 47% of US stocks

EV / EBITDA
−1.4×

Cheaper than 71% of US stocks

Growth & margins
Revenue growth (YoY)
73.0%

Higher than 90% of US stocks

Earnings growth (YoY)
—
Gross margin
—
Operating margin
−502.0%

Higher than 8% of US stocks

Net margin
−296.9%

Higher than 1% of US stocks

Returns & dividend
Return on equity
−78.8%

Higher than 16% of US stocks

Return on assets
−38.0%

Higher than 11% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Wave Life Sciences, Inc. (WVE) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Wave Life Sciences, Inc. has a market value of $706.1M and an enterprise value of $318.6M.

  • Revenue in the twelve months to 30 June 2026: $65.4M. The latest quarter grew 73.0% year on year.

  • Net income over the same four quarters: −$202.5M, a −309.7% net margin.

  • Diluted earnings per share, trailing twelve months: $−1.09.

  • Free cash flow in the twelve months to 30 June 2026: −$193.1M.

  • Shares outstanding: 193.3M.

  • Trailing P/E: −3.0×; forward P/E: −3.0× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Wave Life Sciences, Inc. employs 317 people — $206K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 4 Nov 2026

Data provided by Twelve Data

Peers

WVE vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
WVEWave Life Sciences, Inc.$706.1M22
ACHVAchieve Life Sciences, Inc.$690.9M36
SLBTSL Science Holding Ltd.$684.1M0
ATTOAttovia Therapeutics, Inc.$696.0M0
DNAGinkgo Bioworks Holdings, Inc.$696.9M42
SGMTSagimet Biosciences, Inc.$699.9M44
SLDBSolid Biosciences, Inc.$660.2M43

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Wave Life Sciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest WVE news & analysis

WAVE Life Sciences Targets Genetic Liver Disease With WVE-008 RNA Editing Program

MarketBeat · 4 Nov 2026neutral

At its 2026 Research Day, WAVE Life Sciences outlined plans for WVE-008, an RNA-editing candidate for liver disease associated with the PNPLA3 I148M genetic variant. The company also provided updates on its RNA interference, extrahepatic delivery and bifunctional oligonucleotide platforms.

Why it matters — The update gives WVE watchers information about the development plans for a genetic liver disease candidate and the company’s other platform programs.

Wave Life Sciences, Inc. (WVE) Q3 2026 Earnings Call Transcript

Seeking Alpha · 27 Oct 2026neutral

Seeking Alpha published a transcript of Wave Life Sciences, Inc.’s Q3 2026 earnings call. The provided excerpt contains only the transcript title and no details from the call.

Why it matters — WVE watchers can note the transcript’s availability, but the excerpt provides no information about the company’s quarterly results or commentary.

WAVE Life Sciences Q3 Earnings Call Highlights

MarketBeat · 27 Oct 2026neutral

WAVE Life Sciences reported higher third-quarter revenue and a wider net loss, alongside increased investment in clinical programs spanning obesity, alpha-1 antitrypsin deficiency and liver disease.

Why it matters — The results reflect both revenue growth and higher costs as the company invests in its clinical programs.

Wave Life Sciences (WVE) Reports Q3 Loss, Tops Revenue Estimates

Zacks Investment Research · 27 Oct 2026positive

Wave Life Sciences reported a Q3 loss of $0.30 per share, compared with the Zacks Consensus Estimate of a $0.34 loss. The loss was $0.32 per share in the year-ago quarter.

Why it matters — WVE watchers may note that the reported per-share loss was smaller than the consensus estimate, while still representing a loss.

FAQ

Frequently asked questions about WVE stock

What is the WVE stock price forecast for 2026-2027?

The 21 Wall Street analysts covering Wave Life Sciences, Inc. have a median 12-month price target of $14, with estimates ranging from $10 to $44. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is WVE stock a buy right now?

Of the 21 analysts covering Wave Life Sciences, Inc., 19 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Wave Life Sciences, Inc. 22 out of 100 across roughly 4,600 US stocks as at 3 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank WVE?

As at 3 Nov 2026, Wave Life Sciences, Inc. ranks 22 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (79 of 100).

Will WVE stock go up?

No one can know that. What the data says: the median 12-month target from 21 analysts implies +286.7% from the last close, and Ticker Nerd's factor model ranks Wave Life Sciences, Inc. 22 out of 100 as at 3 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the WVE stock forecast for 2030?

No analyst covering Wave Life Sciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for WVE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $44 over the next 12 months.

How has WVE stock performed over the past year?

Wave Life Sciences, Inc. returned -54.8% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Wave Life Sciences, Inc. do?

Wave Life Sciences Ltd. is a biotechnology company focused on unlocking the potential of RNA medicines, specifically oligonucleotides targeting ribonucleic acid to transform human health.

What is the latest news on WVE?

The most recent item we track (MarketBeat, 4 Nov 2026): "WAVE Life Sciences Targets Genetic Liver Disease With WVE-008 RNA Editing Program". At its 2026 Research Day, WAVE Life Sciences outlined plans for WVE-008, an RNA-editing candidate for liver disease associated with the PNPLA3 I148M genetic variant. The company also provided updates on its RNA interference, extrahepatic delivery and bifunctional oligonucleotide platforms.

Company

About Wave Life Sciences, Inc.

Wave Life Sciences Ltd. is a biotechnology company focused on unlocking the potential of RNA medicines, specifically oligonucleotides targeting ribonucleic acid to transform human health. It leverages its proprietary PRISM platform, which integrates multiple RNA-targeting modalities such as RNA editing, splicing, antisense silencing, and RNA interference, along with chemistry innovation and insights from human genetics. This enables the development of first- or best-in-class therapeutics for both rare and prevalent disorders. The company's pipeline features clinical programs addressing Alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, and Huntington’s disease, as well as preclinical efforts in obesity. These initiatives target diseases originating in the liver, muscle, central nervous system, and other tissues, aiming to deliver disease-modifying therapies with life-changing potential. Founded in 2012 and headquartered in Cambridge, Massachusetts, with operations in Singapore, Wave Life Sciences Ltd. plays a key role in advancing precision medicine for genetic conditions through innovative RNA-based approaches.

CEO Dr. Paul B. Bolno M.B.A., M.D. · 317 employees · United States · https://wavelifesciences.com